None of these are likely in the near term
Retatrutide is an investigational compound not yet approved by Health Canada or the FDA
Being thorough and organized is key
The primary benefits of liraglutide include: Clinically meaningful weight loss (6 to 8% average, up to 10%+ in early responders) Improved glycemic control and HbA1c reduction in type 2 diabetes Demonstrated cardiovascular risk reduction (13% reduction in MACE in the LEADER trial) Reduced progression from prediabetes to type 2 diabetes Approved for adolescents aged 12+ (obesity) and children aged 10+ (diabetes) The longest safety track record of any GLP-1 receptor agonist How It Works GLP-1 Receptor Activation Liraglutide functions as a potent agonist at GLP-1 receptors distributed throughout the pancreas, brain, heart, and gastrointestinal tract
Wegovy is available as a higher strength, 2.4 mg once weekly, which may be more effective for weight loss
Since Semaglutide GLP-1 has a long half-life, one injection per week is sufficient, making it a convenient option compared to daily medications